Subgroup	Endocrine therapy	Observation	HR	95% CI	Favors Endocrine therapy	Favors observation
Age						
< 50	119	120	0.53	(0.39-0.72)	-	
≥50	102	101	0.57	(0.40-0.82)	-	
ECOG-PS						
0-1	201	197	0.53	(0.42 - 0.67)	-	
2	20	24	0.71	(0.35-1.45)		_
Menopausal	status					
Pre	120	122	0.61	(0.45-0.83)	-	
Post	101	99	0.44	(0.31-0.63)	-	
Ki67 status						
<14	27	20	0.50	(0.22-1.12)		-
≥14	135	124	0.70	(0.51-0.96)	-	
Bone metasta	asis					
Yes	107	107	0.66	(0.48-0.91)	_ <b>_</b> _	
No	114	114	0.47	(0.35-0.64)	-	
Liver metasta	asis					
Yes	51	66	0.67	(0.44-1.02)	-	
No	170	155	0.53	(0.40-0.71)	-	
Pulmonary n	netastasis					
Yes	65	70	0.59	(0.40 - 0.88)	-	
No	156	151	0.53	(0.40-0.70)	-	
Brain metasta	asis					
Yes	9	17	0.77	(0.33-1.80)		
No	212	204	0.56	(0.44-0.72)	-	
Soft tissue m	etastasis					
Yes	10	9	0.47	(0.16-1.37)		_
No	86	73	0.76	(0.48-1.19)	-	-
Lymph node	metastasis					
Yes	64	84	0.68	(0.47 - 0.99)	-	
No	157	137	0.50	(0.37-0.67)	-	
Number of m	netastases					
1 or 2	180	172	0.53	(0.40 - 0.70)	-	
≥3	41	49	0.67	(0.43-1.05)	-	
Best response	e to first-line systemic trea	itment				
Objective re	espond 111	120	0.46	(0.32 - 0.66)	-	
Stable disea		101	0.68	(0.50-0.93)	-	
Orverna <sup>11</sup>	221	221	0.55	(0.44.0.60)	_	
Overall	221	221	0.55	(0.44-0.69)	-	
					0.2 0.5 1	2 5
					0.2 0.5 1	- 3

**S7 Fig.** Subgroup analysis between endocrine therapy maintenance and observation in multicenter cohort. ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence interval; HR, hazard ratio.